Evidence map›Paper›PMID 36290941›Full record

ArticleBiosensors2022

In Silico Investigation of SNR and Dermis Sensitivity for Optimum Dual-Channel Near-Infrared Glucose Sensor Designs for Different Skin Colors.

Murad Althobaiti

Abstract read
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Murad AlthobaitiBiomedical Engineering Department, College of Engineering, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.ORCID 0000-0002-8084-6916

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a serious health condition that requires patients to regularly monitor their blood glucose level, making the development of practical, compact, and non-invasive techniques essential. Optical glucose sensors-and, specifically, NIR sensors-have the advantages of being non-invasive, compact, inexpensive, and user-friendly devices. However, these sensors have low accuracy and are yet to be adopted by healthcare providers. In our previous work, we introduced a non-invasive dual-channel technique for NIR sensors, in which a long channel is utilized to measure the glucose level in the inner skin (dermis) layer, while a short channel is used to measure the noise signal of the superficial skin (epidermis) layer. In this work, we investigated the use of dual-NIR channels for patients with different skin colors (i.e., having different melanin concentrations). We also adopted a Monte Carlo simulation model that takes into consideration the differences between different skin layers, in terms of blood content, water content, melanin concentration in the epidermis layer, and skin optical proprieties. On the basis of the signal-to-noise ratio, as well as the sensitivities of both the epidermis and dermis layers, we suggest the selection of wavelengths and source-to-detector separation for optimal NIR channels under different skin melanin concentrations. This work facilitates the improved design of a compact and non-invasive NIR glucose sensor that can be utilized by patients with different skin colors.

Indexed as

MelaninsSkin PigmentationBlood GlucoseDermisHumansSkinWaterBlood GlucoseMelaninsWaterbioinstrumentationdual-channelglucosenear-infraredNIR technologysensors

Identifiers

PMID36290941
PMCPMC9599199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.